Urinary B-Type Natriuretic Peptide Levels in the Diagnosis and Prognosis of Heart Failure

详细信息    查看全文

• 作者：Raquel Corté ; s ; Miguel Rivera ; Antonio Salvador ; Fern ; o Garc&#xed ; a de Burgos ; Vicente Bertomeu ; Esther Roselló ; -Llet&#xed ; Lu&#xed ; s Mart&#xed ; nez-Dolz ; Rafael Payá ; Luis Almenar ; Manu
• 关键词：Neurohormonal ; natriuretic peptides ; urine ; New York Heart Association classification
• 刊名：Journal of Cardiac Failure
• 出版年：2007
• 出版时间：September 2007
• 年：2007
• 卷：13
• 期：7
• 页码：549-555
• 全文大小：241 K

文摘

Plasma B-type natriuretic peptide (BNP) is a useful biomarker for diagnosis and prognosis of heart failure (HF); however, urine BNP has never been calculated. We sought to compare urinary and plasma BNP levels and to investigate the potential diagnostic and prognostic value of this peptide in HF.

Methods and Results

Urine and plasma BNP levels were measured in 92 HF patients and 30 control subjects. Urinary BNP levels were higher in HF patients than in control subjects (P < .0001), correlating with plasma BNP levels (r = 0.64, P < .0001). Urine BNP was a good tool for the diagnosis of HF, the area under the curve (AUC) being 0.91 ± 0.06 (P < .0001). Urinary BNP levels had prognostic power for cardiac events (cardiac admissions + mortality) with an odds ratio of 6.6 (P < .05). To determine the prognostic power of urinary BNP in detecting 12-month cardiac mortality, we obtained an AUC of 0.76 ± 0.6 (P = .014).

Conclusions

The data suggest that urine BNP is a new candidate marker for diagnosis and prognosis of HF mortality and cardiac events. This raises the possibility of using this relatively simple noninvasive test in primary care settings or in specific conditions where the collection of blood samples could be difficult.